C12Y 304/21042
Complement subcomponent c1s
Official title: Complement subcomponent C1s (3.4.21.42)
C12Y304/21042 (Complement subcomponent c1s) appears on 16 US grants and 24 published applications in this corpus.
Search patents in C12Y- Granted patents
- 16
- Published applications
- 24
- Assignees
- 5
- Inventors
- 23
- Latest grant
- 24 Feb 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2014 | 1 | 3 |
| 2015 | 4 | 4 |
| 2016 | 1 | 1 |
| 2017 | 2 | 2 |
| 2018 | 0 | 1 |
| 2019 | 2 | 0 |
| 2020 | 1 | 4 |
| 2021 | 0 | 1 |
| 2022 | 1 | 2 |
| 2023 | 1 | 1 |
| 2024 | 0 | 2 |
| 2025 | 2 | 2 |
| 2026 | 1 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Complement component 1s (C1s) deficient cells for production of vaccines and biopharmaceutical proteins24 Feb 2026US 12,559,526 B2The Regents of the University of California
- Anti-complement C1s antibodies and uses thereof4 Mar 2025US 12,240,917 B2Bioverativ USA Inc.
- Anti-complement C1s antibodies and uses thereof4 Feb 2025US 12,215,169 B2Bioverativ USA Inc.
- Methods for quantitation of functional C1 esterase inhibitor (FC1-INH)12 Sep 2023US 11,754,570 B2Takeda Pharmaceutical Company Limited
- Polynucleotides encoding anti-C1s antibodies15 Feb 2022US 11,246,926 B2Bioverativ USA Inc.
- Expression cassette for target gene and use thereof12 Feb 2026US 2026/0041794 A1Suzhou Heguang Kehui Biotechnology Co., Ltd
- Anti-complement c1s antibodies and uses thereof21 Aug 2025US 2025/0263503 A1Bioverativ USA Inc.
- Anti-complement c1s antibodies and uses thereof12 Jun 2025US 2025/0188192 A1Bioverativ USA Inc.
- An antibody, a pharmaceutical composition, and a method21 Mar 2024US 2024/0092889 A1
- Reducing surgery-associated hemolysis in cold agglutinin disease patients15 Feb 2024US 2024/0052062 A1Bioverativ USA Inc.
Most cited
By later US patents
- Anti-complement C1s antibodies17US 8,945,562 B2True North Therapeutics, Inc. · 2015
- Anti-complement C1s16US 8,877,197 B2True North Therapeutics, Inc. · 2014
- Methods of inhibiting activation of complement component C4 with anti-C1s antibodies13US 9,074,003 B2True North Therapeutics, Inc. · 2015
- Methods of inhibiting activation of complement component C4 with anti-C1s antibodies13US 9,074,004 B2True North Therapeutics, Inc. · 2015
- Methods of inhibiting complement C4 activation with anti-complement C1S antibodies12US 9,206,259 B2True North Therapeutics, Inc. · 2015